Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital
About this trial
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.
Eligibility criteria
Qualifiers
The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring.
Neutrophil engraftment
Received at least one MRD monitoring by digital PCR after HSCT
Disqualifiers
Patients who relapsed or died before the first digital PCR monitoring
Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
Trial design
Treatments tested in this trial
- Digital PCR
- Quantitative PCR
- MFC
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov